Market Cap (In SEK)
78.2 Million
Revenue (In SEK)
10.66 Million
Net Income (In SEK)
-41.95 Million
Avg. Volume
468.36 Thousand
- Currency
- SEK
- Country
- Healthcare
- Open
- -
- Prev. Close
- -
- Day Range
- -
- Year Range
- 0.995254-4.03
- PE
- -2.67
- EPS
- -0.4
- Beta Value
- 0.714
- ISIN
- SE0009723125
- CUSIP
- -
- CIK
- -
- Shares
- 73091300.0
- Earnings Annoncement
- -
Company Profile
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Dr. Mathias Svahn Ph.D.
- Employee Count
- -
- Website
- https://www.nextcellpharma.com
- Ipo Date
- 2017-07-13
- Details
- NextCell Pharma AB, a biopharmaceutical company, engages in the research and development of novel stem cell therapies in Sweden. The company develops ProTrans, a drug candidate comprising stem cells primarily for treating autoimmune and inflammatory diseases. It also provides Cellaviva, a stem cell bank for the family-saving of stem cells from umbilical cord blood and umbilical cord tissue. NextCell Pharma AB was incorporated in 2014 and is based in Huddinge, Sweden.
More Stocks
-
ZYXIZynex, Inc.
ZYXI
-
NNSB
-
4563AnGes, Inc.
4563
-
300321
-
RILYG
-
4078
-
CNXNPC Connection, Inc.
CNXN
-
FRWDF